SELFCHECK
Lyme Disease Test
Lyme Disease Test
Anti-Borrelia IgM antibody finger-prick rapid blood test
Buy 1 Get 1 half price
Buy 1 Get 1 half price
Order 2 tests and get the lower priced test for 1/2 price
UK delivery £3.95 (FREE for orders over £25)
UK delivery £3.95 (FREE for orders over £25)
Order before 2pm Monday to Friday for same day dispatch (except holidays). All orders dispatched with Royal Mail 24*
Plain packaging
Plain packaging
Discreet plain packaging on all orders.
Important: Whether positive or negative, a self-test result is a starting point for a conversation about your symptoms with your doctor, but is not a diagnosis. Always speak with your doctor if you are concerned about your symptoms or anxious about your health.
Couldn't load pickup availability
Intended use
The SELFCHECK Lyme Disease Test is registered with MHRA as a CE certified, in-vitro diagnostic medical device for self-testing.
- Finger-prick blood test
- Safe and easy to use
- Results at home in minutes
- CE certified for self-test use
Contains 1 test.
The test is a manual, qualitative, immunochromatographic (lateral flow), screening self-test for the immunological detection of anti-Borrelia immunoglobulin M (IgM) antibodies in a finger prick whole blood sample. The test is intended for home use by the general public to screen for IgM antibodies to Borrelia bacteria following a recent tick bite.
General information
Lyme disease is an infection caused by Borrelia bacteria, which are spread to humans by tick bites. Ticks are tiny spider-like creatures often found in UK woodlands, parks and gardens.
It can take the body two to four weeks to produce detectable levels of antibodies after a bite. IgM antibodies are produced first, which increase to a maximum level after about six weeks, but then begin to decline.
Once transmitted, Borrelia bacteria can affect the nervous system, potentially leading to severe neurological disorders. An infection can manifest as skin lesions and arthritis. A characteristic redness of the skin, accompanied by inflammation, may appear at the bite site within three to ten days, or even several weeks post-bite, and may be accompanied by fever.
Upon Borrelia infection, the immune system elicits a response characterised by the production of specific antibodies in the blood stream. Immunoglobulin M (IgM), the initial antibody isotype to appear, is detectable within a two to six week post-infection window.
Lyme disease exhibits a triphasic progression. During the initial phase (two to four weeks), IgM antibodies are demonstrable in 40 to 60% of affected individuals. In the subsequent phase (four to six weeks post-initial phase), antibody detection rates increase to 70 to 90%. In the final phase, antibodies are typically present and readily detectable.
If diagnosis and treatment is delayed, some people may develop more severe symptoms months or years after being infected.
Time to result
The test gives a result in 10 minutes at home.
Warnings
A screening test for a single biomarker, such as IgM anti-Borrelia antibodies, is not a diagnosis.
Do not change your medication, diet or lifestyle solely on the basis of a self-test - always discuss your result with an appropriate healthcare professional first.
Not following the instructions exactly as written in the instructions for use may cause a false positive or false negative result.
In the event of a positive result, this screening test does not determine the stage of illness.
IgM antibody tests for Borrelia, whether performed at home with a self-testing kit, or by a hospital laboratory, have significant limitations due to frequent false positive results, including individuals who are sero-positive for cytomegalo-viruses (CMV), Epstein Barr virus, (EBV), herpes simplex virus (HSV), syphilis, leptospirosis, mononucleosis or autoimmune disorders. A self-test result for anti-Borrelia IgM antibodies by itself should be viewed with caution until it is followed up by a consultation with a doctor.
Whether you have a positive or negative self-test result, you must ask for an urgent GP appointment If you have symptoms of Lyme disease and think you may have been bitten by a tick.
Accuracy
The test has an overall agreement of 89.19% (81.14-94.46)*, sensitivity of 89.09%, and specificity of 89.29% with laboratory tests for anti-Borrelia IgM antibodies. Although this test is reliable for the detection of anti-Borrelia IgM antibodies, all medical tests can give false positive or false negative results.
IMPORTANT: These figures refer to the agreement of the SELFCHECK test with laboratory anti-Borrelia IgM antibody tests, and not to the accuracy of tests for the diagnosis of Lyme disease.
*95% confidence interval.
Further information
Information on Lyme disease, Borrelia infection and related diseases:
www.nhs.uk/conditions/lyme-disease
Information for health care professionals
Principle, performance data, and regulatory information on the SELFCHECK Lyme Disease Test for health care professionals.
Updated 14th April 2026
What SELFCHECK users say
What SELFCHECK users say
We invited SELFCHECK customers to tell us about their experience with their SELFCHECK test.
- 4/5 overall rating
- 9/10 easy to read instructions
- 4/5 thought that using the test was worthwhile
"All appeared good and instructions easy to follow"
"Everything was easy to follow"
"Very satisfied with your service"
"Simple enough, just had to check the instructions a couple of times"
The survey was completed in the Summer of 2024 of 118 random respondents who purchased one of our SELFCHECK tests. All customers are provided with contact information for our customer care team with their test, if they need any help to use their SELFCHECK test, or help to interpret their results.
For further information on how the scores were calculated please contact SELFCHECK.
Information for doctors
Information for doctors
SELFCHECK has been a leading British brand of health checks for over 15 years.
At SELFCHECK, we're working hard to make self-testing better for your patients. All our medical tests are assembled at a quality assured (ISO13485) medical device facility in France, and registered with MHRA according to UK medical device regulations IVDD/IVDR.
We are working closely with the NHS and academia to develop new diagnostics at our own UK R&D labs, particularly in the areas of sepsis, and the monitoring of chronic diseases.
Our professional customer care team provide help for your patients, so they can fully understand how our tests work, and how they should be used.
